Karyopharm Therapeutics Inc. (KPTI)

NASDAQ: KPTI · USD

$0.83

+0.35 (+73.4%)· Recorded snapshot

Market cap	18.9M
Revenue (ttm)	146.6M
Net income (ttm)	-224.7M
EPS (ttm)	-$11.6
Shares out	22.7M
Volume	46,830,431
Beta	1.04

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 146.6M
Net income (ttm): -224.7M
EPS (ttm): -$11.6
Market cap: 18.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROIC-437

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All KPTI indicators

Market & fundamental data

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001503802
Company name	Karyopharm Therapeutics Inc.
Country	United States
Country code	US
CUSIP number	48576U205
Earnings date	2026-11-10
Earnings time	bmo
Employees	228
Employees change	-51
Employees growth	-18.28%
Enterprise value	$282.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2008
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2013-11-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US48576U2050
Last 10-K release date	2026-02-13
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split date	2025-02-26
Last stock split type	Reverse
Market cap	$18.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$0.83
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	KPTI
U.S. state	Massachusetts
Website	https://www.karyopharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-1,391.34%
EV/Sales	1.89x
FCF / EV yield	-23.56%
FCF yield	-468.62%
Forward EV/Sales	1.99x
Forward P/S	0.1x
P/S ratio	0.1x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-56.17%
EBITDA margin	-56.06%
Gross margin	99.06%
Operating margin	-56.17%
Pretax margin	-153.3%
Profit margin	-153.28%
Profit per employee	$-985,702
Revenue per employee	$643,075
ROA	-47.61%
ROA (5Y)	-30.43%
ROCE	359.36%
ROIC	-437.05%
SBC / revenue	7.94%
Tax / revenue	-0.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	0
Gross profit growth	4.74%
Gross profit growth (Q)	-17.11%
Gross profit growth 3Y	-3.04%
Net income growth years	0
Revenue growth	6.81%
Revenue growth (Q)	-11.86%
Revenue growth (QoQ)	-4.66%
Revenue growth 10Y	97.92%
Revenue growth 3Y	0.14%
Revenue growth 5Y	7.47%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$149,000
EBIT	$-82.4M
EBITDA	$-82.2M
EPS	$-11.58
FCF per share	$-2.88
Financing cash flow	$78.6M
Free cash flow	$-65.3M
Free cash flow minus SBC	$-77M
Gross profit	$145.2M
Income taxes	$-32,000
Investing cash flow	$3M
Net borrowing	$27M
Net cash flow	$16.2M
Net income	$-224.7M
Operating cash flow minus SBC	$-77M
Operating income	$-82.4M
Revenue	$146.6M
Stock-based compensation	$11.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-24.52
Book value per share	$-14.56
Interest coverage	-1.67
Long-term assets	$4.9M
Long-term liabilities	$307.3M
Net cash (debt)	$-263.4M
Net cash / market cap	-1,889.09%
Piotroski F-Score	2
Property, plant and equipment	$4.4M
Shareholders' equity	$-330.2M
Tangible book value	$-330.2M
Tangible book value per share	$-14.56
Total assets	$111.3M
Total cash	$65.1M
Total debt	$328.5M
Total liabilities	$441.5M
WACC	11.78%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.36
Current assets	$106.4M
Current liabilities	$134.2M
Current ratio	0.79
Inventory turnover	0.31
Net working capital	$-51.6M
Quick ratio	0.71
Working capital	$-27.9M
Working capital turnover	-10.04

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-129.56%
Dividend yield	0%
Shareholder yield	-129.56%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.37%
10Y return CAGR	-39.77%
10Y total return	-99.37%
150-day SMA	$5.55
1D price change	73.42%
1M price change	-54.33%
1M total return	-54.33%
1W price change	106.33%
1W total return	106.33%
1Y price change	-88.48%
1Y return CAGR	-88.49%
1Y total return	-88.48%
20-day SMA	$0.54
200-day SMA	$6.10
3M price change	-89.56%
3M total return	-89.56%
3Y price change	-94.02%
3Y return CAGR	-60.88%
3Y total return	-94.02%
50-day SMA	$1.27
50-day SMA vs 200-day SMA	50under200
52-week high	$10.99
52-week high date	2026-02-24
52-week low	$0.31
52-week low date	2026-10-15
5Y price change	-99.05%
5Y return CAGR	-60.63%
5Y total return	-99.05%
6M price change	-91.46%
6M total return	-91.46%
After-hours change	-1.49%
After-hours close	$0.83
After-hours price	$0.82
All-time high	$735.08
All-time high date	2014-12-08
All-time low	$0.31
All-time low date	2026-10-15
Average true range (ATR)	$0.13
Average volume	3.6M
Beta (1Y)	2.21
Beta (2Y)	1.79
Beta (5Y)	1.04
Change from 52-week high	-92.43%
Change from 52-week low	168.52%
Change from all-time high	-99.9%
Change from all-time low	138.68%
Change from open	77.48%
Day's gap	-2.29%
Dollar volume	$39M
High price	$0.91
Low price	$0.47
Monthly RSI	35.23
Open price	$0.47
Position in 52-week range	83.33%
Premarket change	-0.02%
Premarket close	$0.48
Premarket price	$0.48
Premarket volume	460
Previous close	$0.48
Price vs 150-day SMA	-86.66%
Price vs 20-day SMA	38.02%
Price vs 200-day SMA	-87.88%
Price vs 50-day SMA	-41.56%
Relative volume	13.08
RSI	45.26
Sharpe ratio	-0.68
Sharpe ratio (3Y)	-0.26
Sharpe ratio (5Y)	-0.31
Sortino ratio	-0.83
Sortino ratio (3Y)	-0.33
Sortino ratio (5Y)	-0.39
Volume	46.8M
Weekly RSI	29.46
YTD price change	-89.95%
YTD total return	-89.95%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	17.3M
Float percentage	76.26%
Shares change (QoQ)	17.09%
Shares change (YoY)	129.56%
Shares held by insiders	2.86%
Shares held by institutions	80.52%
Shares outstanding	22.7M
Short % of float	42.01%
Short % of shares	32.04%
Short ratio	4.2 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	503

Deeper analysis on KPTI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KPTI report

Is a complete KPTI research report available?

No complete published report is available for Karyopharm Therapeutics Inc. (KPTI) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Karyopharm Therapeutics Inc. (KPTI)

Price

Financial snapshot

Fair-value bridge

Latest news · KPTI

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KPTI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on KPTI

Frequently asked questions